-
Views
-
Cite
Cite
Francisco J. López, Robert J. Ardecky, Bruce Bebo, Khalid Benbatoul, Louise De Grandpre, Sha Liu, Mark D. Leibowitz, Keith Marschke, Jon Rosen, Deepa Rungta, Humberto O. Viveros, Wan-Ching Yen, Lin Zhi, Andrés Negro-Vilar, Jeffrey N. Miner, LGD-5552, an Antiinflammatory Glucocorticoid Receptor Ligand with Reduced Side Effects, in Vivo, Endocrinology, Volume 149, Issue 5, 1 May 2008, Pages 2080–2089, https://doi.org/10.1210/en.2007-1353
- Share Icon Share
Treatment of inflammation is often accomplished through the use of glucocorticoids. However, their use is limited by side effects. We have examined the activity of a novel glucocorticoid receptor ligand that binds the receptor efficiently and strongly represses inflammatory gene expression. This compound has potent antiinflammatory activity in vivo and represses the transcription of the inflammatory cytokine monocyte chemoattractant protein-1 and induces the antiinflammatory cytokine IL-10. The compound demonstrates differential gene regulation, compared with commonly prescribed glucocorticoids, effectively inducing some genes and repressing others in a manner different from the glucocorticoid prednisolone. The separation between the antiinflammatory effects of LGD-5552 and the side effects commonly associated with glucocorticoid treatment suggest that this molecule differs significantly from prednisolone and other steroids and may provide a safer therapeutic window for inflammatory conditions now commonly treated with steroidal glucocorticoids.